Skip to main content
. 2009 Feb 25;206(4):575–585. doi: 10.1007/s00213-009-1484-9

Table 1.

Candidate sites for modulation of aberrant networks

Cellular target Candidate site Clinical efficacy Status
Pyramidal cell mGluR2/3 ( +) high Phase IIb clinical
NR2B (−) Early clinical
α2 GABAA (+) Early clinical
α5 GABAA (+) Preclinical
Interneuron D1 (+) Early clinical
Astrocyte PAR1 (−) Preclinical
mGluR1/5 (−) Preclinical

Negative sign (−) antagonist, positive sign (+) agonist/positive modulator